GSA Capital Partners LLP Takes Position in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 103,618 shares of the biotechnology company’s stock, valued at approximately $1,862,000.

A number of other institutional investors and hedge funds have also modified their holdings of SRPT. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $25,000. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics during the third quarter worth $25,000. Ancora Advisors LLC boosted its position in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares in the last quarter. Allworth Financial LP grew its holdings in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, July 9th. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $18.10 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The stock has a fifty day moving average of $17.08 and a two-hundred day moving average of $18.37. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -6.24, a PEG ratio of 0.24 and a beta of 0.24. Sarepta Therapeutics, Inc. has a fifty-two week low of $14.68 and a fifty-two week high of $25.32.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.